<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02614534</url>
  </required_header>
  <id_info>
    <org_study_id>FCO-HIP-2015-01</org_study_id>
    <nct_id>NCT02614534</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma</brief_title>
  <acronym>HIPECT4</acronym>
  <official_title>Multicentre, Randomized Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimónides Biomedical Research Institute of Córdoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimónides Biomedical Research Institute of Córdoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Hyperthermic Intra-peritoneal Chemotherapy
      (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal
      carcinoma is effective in the treatment of locally advanced colorectal carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether Hyperthermic Intra-peritoneal Chemotherapy
      (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal
      carcinoma is effective in the treatment of locally advanced colorectal carcinoma.

      The Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) is expected to be an effective
      treatment with minimal side effects, it has already provided clear benefits in terms of
      overall survival in patients with advanced cancer.

      This is an attractive option for the healthcare professionals who face daily to peritoneal
      recurrence after performing complex surgeries, however its application is difficult due to
      the cost and resources increase. This leads to the necessity of administering the treatment
      within a clinical trials and in order to obtain a significant power this clinical trials will
      be multicenter and it will be performed in several Oncological surgery Units highly
      specialised and with extensive experience in colorectal carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2015</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Locoregional Control (LC)</measure>
    <time_frame>3 years</time_frame>
    <description>Time elapsed from the surgical intervention clinical up to the date the patient is free of clinical and radiological locoregional recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months and 36 months after surgery</time_frame>
    <description>Evaluate the effect of the addition of HIPEC with Mitomycin C to cytoreductive surgery in 12 months and 3 years overall survival rate (%OS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>12 months and 36 months after surgery</time_frame>
    <description>Evaluate the effect of addition of HIPEC with Mitomycin C to cytoreductive surgery in 12 months and 3 years disease free survival rate (% DFS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the morbidity and mortality related with the treatment</measure>
    <time_frame>36 months after surgery</time_frame>
    <description>Evaluate the safety (treatment-related morbidity and mortality) of addition of HIPEC with Mitomycin C to cytoreductive surgery in locally advanced colo-rectal cancer. It will be measured by the incidence rate of adverse events and deaths.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIPEC technique operating time</measure>
    <time_frame>36 months after surgery</time_frame>
    <description>Average operating time calculation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIPEC technique length of hospital stay</measure>
    <time_frame>36 months after surgery</time_frame>
    <description>Average length of hospital stay calculation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIPEC technique re-admission rate</measure>
    <time_frame>36 months after surgery</time_frame>
    <description>Average re-admission rate calculation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIPEC technique laparoscopic vs laparotomy approach</measure>
    <time_frame>36 months after surgery</time_frame>
    <description>With this outcome it will be calculated the frequency of both surgery techniques and if it has any impact on the locoregional control of the disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIPEC technique open vs. closed HIPEC technique</measure>
    <time_frame>36 months after surgery</time_frame>
    <description>With this outcome it will be calculated the frequency of both surgery techniques and if it has any impact on the locoregional control of the disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire QLQ-C30</measure>
    <time_frame>At baseline, 1 month after surgery, 6 months after surgery, 12 months after surgery, 24 months after surgery and 36 months after surgery</time_frame>
    <description>With this outcome it will be calculated the effect on the quality of life of patients using questionnaire QLQ-C30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaires QLQ-CR29</measure>
    <time_frame>At baseline, 1 month after surgery, 6 months after surgery, 12 months after surgery, 24 months after surgery and 36 months after surgery</time_frame>
    <description>With this outcome it will be calculated the effect on the quality of life of patients using questionnaire QLQ-CR29.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Proactive cytoreductive surgery + HIPEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women) plus HIPEC (Mytomicin C - 60 minutes).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proactive cytoreductive surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MITOMYCIN-C 40 mg</intervention_name>
    <description>Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women) plus HIPEC with Mytomicin C for 60 minutes.</description>
    <arm_group_label>Proactive cytoreductive surgery + HIPEC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Proactive cytoreductive surgery</intervention_name>
    <description>Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women)</description>
    <arm_group_label>Proactive cytoreductive surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients between the ages of 18 and 75 years;

          2. Adenocarcinoma of the colon, sigma and colon-sigma joint which represent cT4a/b in
             line with The American Joint Committee on Cancer: the 7th edition of the AJCC cancer
             staging manual;

          3. Lymph node involvement: N0, the presence of N1/2 according to the 7th edition of the
             AJCC is allowed, provided that they can be resectable;

          4. Metastatic extent: M0;

          5. Karnofsky index &gt;70 or Performance status ≤2;

          6. Informed consent properly completed.

        Exclusion Criteria:

          1. Presence of metastases (M1), in case of liver or peritoneal metastases at the time of
             surgery, the patient will be excluded from the trial and treated according to their
             new stage.

          2. Presence of unresectability criteria;

          3. Urgent intervention due to obstruction or perforation if there is tumor removal, prior
             interventions will be accepted as referrals without primary tumor removal or drainage
             of collections prior to scheduled surgery.

          4. Extraperitoneal rectal cáncer (avoiding alterations for neoadyuvance);

          5. Coexistence of another malignant neoplastic disease (synchronous tumors of the colon
             and upper rectum are accepted as long as the stage is equal to or less than the
             treated tumor).

          6. Severely altered liver, kidney and cardiovascular function;

          7. Intolerance to treatment;

          8. Administration of chemotherapy before the trial (use of neoadyuvance is discarded);

          9. Pregnant or breastfeeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Álvaro Arjona Sánchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Reina Sofía</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Miguel Luque Pineda</last_name>
    <phone>(+34) 957 011 040</phone>
    <email>antonio.luque@imibic.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Sant Joan Despí. Moisès Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Barrios Sánchez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pedro Barrios Sánchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Castellón</name>
      <address>
        <city>Castellón De La Plana</city>
        <state>Castellón</state>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Boldó, MD</last_name>
    </contact>
    <investigator>
      <last_name>Enrique Boldó, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Morales, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rafael Morales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria &quot;Dr. Negrín&quot;</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <state>Islas Canarias</state>
        <zip>35019</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Alonso Gómez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jaime Alonso Gómez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Señora de Candelaria</name>
      <address>
        <city>Santa Cruz De Tenerife</city>
        <state>Islas Canarias</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Concepción Martín, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vanessa Concepción Martín, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Príncipe de Asturias</name>
      <address>
        <city>Alcalá De Henares</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Gutiérrez Calvo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alberto Gutiérrez Calvo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estíbalitz Pérez Viejo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Estíbalitz Pérez Viejo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Torrecárdenas</name>
      <address>
        <city>Almería</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Torres Melero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Juan Torres Melero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Badajoz</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arancha Prada Villaverde, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arancha Prada Villaverde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Sánchez García, MD</last_name>
    </contact>
    <investigator>
      <last_name>Susana Sánchez García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Álvaro Arjona Sánchez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alvaro Arjona, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Ortega Pérez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gloria Ortega Pérez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Villarejo Campos, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pedro Villarejo Campos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Prieto Nieto, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabel Prieto Nieto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Díaz Reques, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eduardo Díaz Reques, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Fabra Cabrera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Reina Sofía</name>
      <address>
        <city>Murcia</city>
        <zip>30003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Ramírez Faraco, MD</last_name>
    </contact>
    <investigator>
      <last_name>María Ramírez Faraco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquín Carrasco, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joaquín Carrasco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso García Fadrique, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alfonso García Fadrique, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Camps, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bruno Camps, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2015</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIPEC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The individual participant data will be available.
Individual parcicipant data that underlie the results reportes in this article, after deidenttification (text, tables, figures and appendices)
The other documents that will be available: study protocol, Statistical Analysis Plan, Informed Consent Form.
The data will be available beginning 9 months and ending 36 months following article publication.
With whom? Researchers who provide a methodologically sound proposal.
For what types of analyses? for individual participant data meta-analysis.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The data will be available beginning 9 months and ending 36 months following article publication.</ipd_time_frame>
    <ipd_access_criteria>To obtain the data, a proposal must be sent to uicec@imibic.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

